

13 December 2017

Company Announcements Office
Australian Securities Exchange

British Medical Ultrasound Society release guidance requiring high level disinfection for all semi critical ultrasound probes

Nanosonics Limited (ASX: NAN) advises that the British Medical Ultrasound Society (BMUS) together with The Society & College of Radiographers in the UK have issued guidance requiring the appropriate disinfection or sterilisation of ultrasound probes.

Published in the Guidelines for Professional Ultrasound Practice. Revision 2, December 2017, BMUS advises that *'All ultrasound transducer probes should be cleaned immediately after a scan to remove all organic matter and body fluids. Ultrasound probes should then undergo appropriate disinfection or sterilisation. All critical probes (probes contacting sterile tissues or blood) should be preferably sterilised, but if sterilisation is not possible, they should be minimally high level disinfected and used with a sterile sheath. All semi critical probes (both semi-invasive probes contacting mucous membranes and non-invasive probes contacting non-intact/broken skin) should be high level disinfected either manually or with automated systems. High level disinfection is still required when using a sheath as sheaths can have micro-perforations or can break.*

The BMUS guidance draws on best practice infection prevention guidance for ultrasound probes previously published by NHS Wales and Scotland as well as more recent guidance from the Health Service Executive of Ireland as well as the joint guidance from the Australasian College for Infection Prevention and Control and Australasian Society for Ultrasound in Medicine, all of which highlight the importance of high level disinfection of all semi-critical ultrasound probes.

"This new guidance from the British Medical Ultrasound Society is a welcome addition to a fast growing number of international guidance documents being released which recognise the importance of high level disinfection of all semi critical ultrasound probes to minimise the risk of cross contamination and improve patient safety," said Michael Kavanagh, Nanosonics' Chief Executive Officer and President. "Our trophon system is already being adopted widely in Scotland and Wales and is well positioned to deliver the decontamination requirements of all ultrasound departments and practices across the UK by delivering an automated, validated system that is compatible with over 1,000 ultrasound probes across all major ultrasound companies."

Michael Kavanagh
CEO / President

For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. For more information about Nanosonics please visit www.nanosonics.com.au